12,538 Shares in REGENXBIO Inc. (NASDAQ:RGNX) Purchased by EntryPoint Capital LLC

EntryPoint Capital LLC purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 12,538 shares of the biotechnology company’s stock, valued at approximately $97,000.

Several other institutional investors have also recently made changes to their positions in the stock. Barclays PLC boosted its holdings in shares of REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 67,948 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares during the last quarter. FMR LLC grew its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the period. Finally, Stifel Financial Corp raised its holdings in shares of REGENXBIO by 13.3% in the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock valued at $1,566,000 after purchasing an additional 17,563 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. HC Wainwright reduced their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Finally, Morgan Stanley increased their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average price target of $32.78.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $7.83 on Monday. REGENXBIO Inc. has a 52-week low of $5.62 and a 52-week high of $21.57. The stock has a market cap of $392.17 million, a PE ratio of -1.56 and a beta of 1.35. The firm has a 50-day moving average of $7.40 and a 200-day moving average of $8.74.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. Equities research analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.